TcrossGlobal

Andexanet alfa for severe bleeding after factor Xa inhibitors: the ANNEXA-4 study

In patients with severe bleeding caused by factor Xa (FXa) inhibitors, treatment with andexanet alfa reduced anti-FXa activity and produced good or excellent hemostasis in 80% of patients, according to the ANNEXA-4 trial. Dr. Truman J. Milling Jr. of Dell Medical School, USA, and colleagues reported in the March 28 issue of Circulation.

The ANNEXA-4 study enrolled 479 patients (mean age 78 years, 54% male, 86% Caucasian) from 85 center...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.